Caredx announces study showing alloseq cfdna highly accurate in detecting rejection in organ transplant patients

Brisbane, calif.--(business wire)--caredx, inc. (nasdaq: cdna) – the transplant company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced findings published in transplant international1 that show the performance of alloseq™ cfdna in detecting allograft rejection was consistent with its allosure® lab developed test. kidney allog.
CDNA Ratings Summary
CDNA Quant Ranking